Table 2.

Treatment-related AEs occurring in at least two patients over the study period

Treatment schedule/OSI-906 dose (mg)
S1S2S3
10–80150300450600750450450600
(n = 12)(n = 4)(n = 23)(n = 4)(n = 13)(n = 6)(n = 4)(n = 3)(n = 10)
Any AE, n (%)4 (25)1 (25)9 (39)2 (50)11 (85)5 (83)1 (25)1 (33)5 (50)
Nausea01 (25)2 (9)1 (25)5 (38)3 (50)01 (33)3 (30)
Vomiting00003 (23)4 (67)01 (33)3 (30)
Diarrhea1 (8)1 (25)1 (4)03 (23)1 (17)003 (30)
Fatigue1 (8)1 (25)3 (23)1 (25)3 (23)0001 (10)
Hyperglycemia003 (13)02 (15)1 (17)001 (10)

NOTE: All the patients who received at least one dose of OSI-906.